HD12 for Advanced Stages
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00265031 |
Recruitment Status :
Completed
First Posted : December 13, 2005
Last Update Posted : June 25, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hodgkin´s Lymphoma | Drug: Cyclophosphamide Drug: Adriamycin Drug: Etoposide Drug: Procarbazine Drug: Prednisone Drug: Vincristine Drug: Bleomycin Procedure: radiation therapy | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | January 1999 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 65 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Hodgkin´s lymphoma (histologically proven)
-
CS(PS) IIB with one or both of the risk factors:
- bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
- extranodal involvement
- CS(PS) III, IV
- written informaed consent
Exclusion Criteria:
- Leukocytes <3000/microl
- Platelets <100000/microl
- Hodgkin´s Disease as "composite lymphoma"
- Activity index (WHO) < grade 2

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00265031
Principal Investigator: | Volker Diehl, Prof. | University of Cologne |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00265031 |
Other Study ID Numbers: |
HD12 |
First Posted: | December 13, 2005 Key Record Dates |
Last Update Posted: | June 25, 2012 |
Last Verified: | August 2007 |
Hodgkin´s Lymphoma advanced stages |
Hodgkin Disease Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Prednisone Cyclophosphamide Etoposide Vincristine Doxorubicin Liposomal doxorubicin Bleomycin |
Procarbazine Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal |